top of page

Analyzing Japan & Korea Biologics Markets: CDMO Prospects

Biologics, a class of pharmaceutical products derived from living organisms, have revolutionized modern medicine, offering innovative treatments for various diseases. The markets for biologics drug substance (DS) and drug product (DP) in Japan and Korea have experienced remarkable revenue growth in recent years. As the demand for these life-changing therapies continues to rise, contract development and manufacturing organizations (CDMOs) are presented with significant opportunities to play a crucial role in the production and supply of biologics. In this blog, we will explore the landscape of the biologics markets in Japan and Korea and highlight the burgeoning CDMO opportunities within this dynamic industry.

The Booming Biologics Markets in Japan and Korea

Japan and Korea have emerged as key players in the global biologics industry, with a rapidly expanding market for both DS and drug product manufacturing. Biologics have gained immense popularity due to their high efficacy, specificity, and potential to treat challenging diseases, such as cancer, autoimmune disorders, and rare genetic conditions. The governments of Japan and Korea have been actively supporting the growth of their biologics sectors, fostering a favorable regulatory environment, and providing incentives to promote research and development in this field.

The Role of Contract Development and Manufacturing Organizations (CDMOs)

CDMOs are vital entities that offer specialized services to pharmaceutical companies, including biopharmaceutical manufacturers. These organizations provide end-to-end support in the development, manufacturing, and distribution of biologics, allowing pharmaceutical companies to focus on their core competencies, such as research and commercialization. CDMOs play a significant role in bridging the gap between biopharmaceutical innovation and market availability, ensuring the efficient and cost-effective production of biologics.

Opportunities in Biologics Drug Substance (DS) Manufacturing

Biologics DS manufacturing involves the production of the active pharmaceutical ingredient (API), which is the biologically active component of the drug. The complexity of biologic APIs requires advanced technologies and expertise. CDMOs can seize opportunities in this sector by providing state-of-the-art facilities, process development capabilities, and adherence to stringent quality standards. As the demand for biologics continues to surge, CDMOs can collaborate with pharmaceutical companies to meet the growing manufacturing requirements and optimize production processes.

Advancements in Biologics Drug Product (DP) Manufacturing

Biologics drug product manufacturing involves the formulation and packaging of the final therapeutic product. This production stage is equally critical, as it directly impacts drug stability, efficacy, and patient convenience. CDMOs can capitalize on this opportunity by investing in cutting-edge manufacturing technologies, sterile filling capabilities, and a deep understanding of product development and regulatory requirements. By offering a comprehensive suite of drug product manufacturing services, CDMOs can attract partnerships with pharmaceutical companies seeking to bring their biologic products to market swiftly and efficiently.

Expanding Market for Advanced Therapies (ATx)

In addition to traditional biologics, the advanced therapies (ATx) market is gaining traction in Japan and Korea. ATx includes cell and gene therapies, which have shown immense potential in treating previously incurable diseases. The ATx market is expected to register substantial revenue growth in the coming years, presenting new opportunities for CDMOs. With their expertise in handling complex manufacturing processes, CDMOs can support the production of cell and gene therapies, contributing to the advancement of medical science and patient care in the region.

Collaboration and Regulatory Compliance

For CDMOs to thrive in the biologics markets of Japan and Korea, collaboration with pharmaceutical companies is key. Building strong partnerships that foster trust, reliability, and innovation is essential to establish a successful presence in the industry. Additionally, ensuring compliance with regulatory standards is of utmost importance to meet the stringent quality requirements of biologics production. CDMOs that prioritize adherence to current good manufacturing practices and other relevant guidelines can position themselves as reliable partners in this highly regulated space.


The biologics drug substance (DS) and drug product (DP) markets in Japan and Korea are experiencing significant revenue growth, presenting abundant opportunities for CDMOs to contribute to this thriving industry. By capitalizing on the rising demand for biologics and advanced therapies, CDMOs can establish themselves as key players in the production and supply of life-changing medications. Emphasizing collaboration, regulatory compliance, and investment in cutting-edge technologies, CDMOs can unlock the potential of the biologics market, positively impacting patient outcomes and advancing medical science in Japan and Korea.

Write to us at Learn how GRG Health is helping clients gather more in-depth market-level information on such topics.


bottom of page